Olsalazine
![]() | |
Names | |
---|---|
Trade names | Dipentum |
Other names | Olsalazine sodium |
Clinical data | |
Drug class | 5-ASA derivative[1] |
Main uses | Ulcerative colitis, Crohn’s disease[1][2] |
Side effects | Numbess, fast heart beat[3] |
Pregnancy category | |
Routes of use | By mouth |
Typical dose | 500mg BID[3] |
External links | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a601088 |
Legal | |
License data |
|
Legal status | |
Pharmacokinetics | |
Protein binding | 99% |
Elimination half-life | 0.9 hours |
Chemical and physical data | |
Formula | C14H10N2O6 |
Molar mass | 302.242 g·mol−1 |
3D model (JSmol) | |
| |
|
Olsalazine, sold under the brand name Dipentum among others, is a medication used to treat ulcerative colitis and Crohn’s disease.[1][2] It is used in people who cannot take sulfasalazine.[1] It is taken by mouth in the form of tablet or capsule.[3] If needed, contents of the capsule can be sprinkled on food.[3]
Side effects are uncommon but include numbess and a fast heart beat.[3] Other side effects may include diarrhea, nausea, heartburn, tiredness, and headache.[1] Caution is advised in kidney problems.[3] It is broken down into mesalazine (5-ASA) in the colon by which it acts.[2] 5-ASA than inhibits cyclooxygenase and lipoxygenase thereby reducing prostoglandin and leukotriene production.[1]
Olsalazine was approved for medical use in the United States in 1990.[1] It is available as a generic medication.[3] In the United Kingdom a months supply costs the NHS around £150 as of 2021.[3] In the United States this amount costs about 1,600 USD.[5]
Medical uses
It is used to treat ulcerative colitis and Crohn’s disease.[1][2]
Dose
In ulcerative colitis, a typical dose is 500mg twice daily after food.[3] Doses up to 3 grams per day; however, may be used.[6]
It is taken by mouth in the form of tablet or capsule.[3] If needed, the contents of the capsule can be sprinkled on food.[3]
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.[1]
Society and culture
Supply
The drug is supplied by UCB Pharma.
Cost
In the UK, a months supply costs the NHS around £144 for the capsule form and £160 for the tablet.[3]
Research
In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.[7]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 "Olsalazine Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 7 November 2021. Archived 18 January 2021 at the Wayback Machine
- ↑ 2.0 2.1 2.2 2.3 "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Archived from the original on 12 January 2021. Retrieved 9 January 2021. Archived 12 January 2021 at the Wayback Machine
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 "1. Gastro-intestinal system". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 47. ISBN 978-0-85711-413-6.
{{cite book}}
: CS1 maint: date format (link) - ↑ 4.0 4.1 "Olsalazine (Dipentum) Use During Pregnancy". Drugs.com. 6 September 2019. Archived from the original on 18 January 2021. Retrieved 9 October 2020. Archived 18 January 2021 at the Wayback Machine
- ↑ "Olsalazine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 7 November 2021.
- ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 47. ISBN 978-0857114105.
- ↑ "Giaconda gets European patent for drug". The Sydney Morning Herald. 28 December 2006. Archived from the original on 25 October 2021. Retrieved 16 January 2021. Archived 25 October 2021 at the Wayback Machine
External links
External sites: | |
---|---|
Identifiers: |
- Pages using duplicate arguments in template calls
- Pages using the JsonConfig extension
- Webarchive template wayback links
- CS1 maint: date format
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Chemicals using indexlabels
- Drugs missing an ATC code
- Drugboxes which contain changes to verified fields
- Articles with changed KEGG identifier
- Articles with changed EBI identifier
- Gastroenterology
- Azo compounds
- Salicylic acids
- RTT